Publications by authors named "Charles Mebus"

Claim this Profile
P
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study.
Nicolino Ruperto, Hermine I Brunner, Zbigniew Zuber, Nikolay Tzaribachev, Daniel J Kingsbury, Charles A Mebus

Pediatr Rheumatol Online J· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Jeffrey R Curtis, Hendrik Schulze-Koops, Liza Takiya, Charles A Mebus, Ketti K Terry

Clin Exp Rheumatol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.
Thomas Stock, Dona Fleishaker, Xin Wang, Arnab Mukherjee, Charles Mebus

Int J Rheum Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Regina Rendas-Baum, Mark Kosinski, Amitabh Singh, Charles A Mebus, Bethany E Wilkinson

Rheumatology (Oxford)· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Josef S Smolen, Daniel Aletaha, David Gruben, Samuel H Zwillich, Sriram Krishnaswami, Charles Mebus

Arthritis Rheumatol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Kim A Papp, James G Krueger, Steven R Feldman, Richard G Langley, Diamant Thaci, Charles Mebus

J Am Acad Dermatol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
Kevin L Winthrop, Joel Silverfield, Arthur Racewicz, Jeffrey Neal, Eun Bong Lee, Charles Mebus

Ann Rheum Dis· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Stanley B Cohen, Andrew Koenig, Lisy Wang, Kenneth Kwok, Charles A Mebus

Clin Exp Rheumatol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
Vibeke Strand, Gerd R Burmester, Cristiano A F Zerbini, Charles A Mebus, Samuel H Zwillich

Arthritis Care Res (Hoboken)· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib for rheumatoid arthritis - Authors' reply.
Gerd R Burmester, Birgitta Benda, David Gruben, John Bradley, Charles Mebus

Lancet· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Gerd R Burmester, Ricardo Blanco, Christina Charles-Schoeman, Jürgen Wollenhaupt, Cristiano Zerbini, Charles Mebus

Lancet· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rinderpest eradication: appropriate technology and social innovations.
Jeffrey C Mariner, James A House, Charles A Mebus, Albert E Sollod, Dickens Chibeu

Science· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.
Thomas C Stock, Bradley J Bloom, Nathan Wei, Saliha Ishaq, Won Park, Charles A Mebus

J Rheumatol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.
Dona L Fleishaker, Juan A Garcia Meijide, Andriy Petrov, Michael David Kohen, Xin Wang, Charles A Mebus

Arthritis Res Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Foot-and-mouth disease in North American bison (Bison bison) and elk (Cervus elaphus nelsoni): susceptibility, intra- and interspecies transmission, clinical signs, and lesions.
Jack Rhyan, Ming Deng, He Wang, Gordon Ward, Thomas Gidlewski, Charles Mebus

J Wildl Dis· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis